Buprenorphine Treatment:
A Training for Multidisciplinary
Addiction Professionals
August 16, 2005
Purpose
The primary goal of this training is to create awareness about buprenorphine among multi-disciplinary addiction professionals. The materials include information designed to increase motivation for bringing buprenorphine to local communities, as well as information about what to expect when someone is treated with this medication. Additionally, materials discuss legislation that permits office-based buprenorphine treatment, the science of addiction, the mechanism of buprenorphine, patient selection issues, and various patient, counseling, and therapeutic issues.
The Blending Initiative
In order to disseminate information to the addiction treatment field, The National Institute on Drug Abuse (NIDA) has created a partnership with the Addiction Technology Transfer Center (ATTC) Network funded by SAMHSA’s Center for Substance Abuse Treatment. The 14 regional ATTCs and the ATTC National Office provide specialized training and technical assistance to the field in order to further develop evidence-based practices and enhance the skills of the substance abuse treatment workforce.
Through the NIDA-SAMHSA Blending Initiative, Blending Teams composed of NIDA researchers and ATTC representatives were created to design dissemination strategies. This training was designed to provide a broad overview of the medication buprenorphine, its effects, and the role of non-physician practitioners in providing and supporting the treatment of individuals receiving this medication.
Objectives
Upon completion, participants involved in the buprenorphine training will be able to:
- Recognize the mechanism of buprenorphine.
- Discuss Opioids 101: Basic information about opioid dependence;
- Review Buprenorphine 101: Overview of the medication and its use;
- Identify patients for buprenorphine treatment;
- Coordinated Care; and
- Demonstrate counseling of buprenorphine patients.
*An annotated bibliography and research articles providing additional information about this exciting new treatment for opioid dependence.
Date and Location
The training will be held August 16, 2005, at the MetroTechnologyCenter, 1900 Springlake Drive, Carousel Room, Oklahoma City. From Interstate 35, take the 36th Street exit and travel west to Martin Luther King Blvd., turn right (north) and you will immediately see the Metro Tech to your left. Parking is on the south and north side of the main building on Martin Luther King Boulevard.
Faculty
Jan Campbell, M.D., is one of 11 doctors in the state of Kansas who is authorized to prescribe buprenorphine. Dr. Campbell is a board-certified general psychiatrist with sub-certification in addiction from the American Board of Psychiatry and Neurology. She has worked in substance abuse treatment in the Kansas City area since 1986, and has been a faculty member at the University of Kansas Medical Center since 1982. Dr. Campbell has experience in both psychopharmacologic and multi-site substance abuse treatment trials and in the management of treatment programs.
Donald McMillan, Ph.D., is a researcher at the University of Arkansas for Medical Sciences (UAMS). His research is directed toward an understanding of the environmental, historical and genetic factors that underlie the acquisition, maintenance and reversal of drug and alcohol abuse. He is known inter-nationally for his expertise on drug abuse treatment and prevention. Dr. McMillan is the retired chairperson of Alcoholism and Drug Abuse Prevention in the Department of Pharmacology and Toxicology.
Continuing Education Credits
Continuing education credit hours have been approved through the Oklahoma State Board of Licensed Social Workers and the Licensed Professional Counselors Committee. Participant evaluation forms must be submitted in order to receive continuing education credit and a certificate of attendance. Certificates of attendance will be distributed at the end of the training. If you need to leave early, please go to the registration desk to pick up your certificate reflecting your hours of attendance. There will be a $5.00 charge for reissuing of certificates.
Special Accommodations
Sign interpreters and/or other special accommodations required by disabled participants will be available upon advance request (please allow one week’s notice). Please indicate on the registration form the type of special accommodations, if any, you require. For requests, call 405-522-8300.
Program Schedule
8:00 a.m.– 9:00a.m.Registration
9:00 a.m. – 9:15 a.m.Opening Remarks and Introductions of Trainers
9:15 a.m. – 10:15 a.m.Module I: Introduction
10:15 a.m. – 10:45 a.m.Module II: Opioids 101
10:45 a.m. – 11:00 a.m.Break
11:00 a.m. –11:45 a.m.Module III: Buprenorphine 101
11:45p.m. – 1:00 p.m.Lunch
1:00 a.m. –1:30 p.m.Module IV: Identification of Patients for Buprenorphine Treatment
1:30 p.m. –2:15 p.m.Module V: Coordinated Care
2:15 p.m. – 2:30p.m.Break
2:30 p.m. – 3:00 p.m.Module V: Coordinated Care (continued)
3:00 p.m. – 4:15 p.m.Module VI: Counseling Buprenorphine Patients
4:15 p.m. – 4:30 p.m.Feedback / Discussion / Evaluation
Seminar Fees
The Buprenorphine Awareness training curriculum and the training itself, is funded by the National Institute of Drug Abuse (NIDA) and the Substance Abuse and Mental Health Services Administration’s Center for Substance Abuse Treatment (CSAT) through the ATTC Network and the Mid-America Addiction Technology Transfer Center (ATTC) at no charge to participants.
Lodging
The following hotel is conveniently located for seminar participants who need overnight accommodations. Let them know you are attending the Department of Mental Health and Substance Abuse Services training.
Oklahoma City:Holiday Inn Hotel and Suites405-843-5558
6200 N. Robinson$66.00/per night
Oklahoma City, OK. 73112
****Complete the form below and mail it to:
Seminar Coordinator
Human Resource Development Division
Institute for Mental Health and Substance Abuse Education and Training
2401 NW 23rd St., Suite 82
Oklahoma City, OK 73107
****Or fax registration to 405/522-8320.
Registration:
Buprenorphine Treatment: August 16, 2005
Name ______
Home Number______
Occupation or Job Title______
Place of Employment______
Address______
City, State, Zip______
Daytime Phone______
E-Mail Address______
Continuing Education Credit Requested:
LPC/LMFT CADC
Psychologist LCSW
StudentOther______
RN/LPNRequire special accommodations as follows:
______